atopic dermatitis

Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.

Aclaris Therapeutics will present previously unreported Phase 2a trial results for ATI-2138, an oral dual ITK/JAK3 inhibitor, at the 2026 AAD Annual Meeting in Denver.

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.

Arcutis reported 2025 revenue of $372.1M (123% growth) and raised 2026 guidance to $480-495M, driven by strong ZORYVE adoption and positive clinical data.

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.

Castle Biosciences' AdvanceAD-Tx test predicts which atopic dermatitis patients will respond to JAK inhibitors, showing 5.5x better outcomes for identified responders versus alternative treatments.